EGFR and non-small cell lung carcinoma: Osimertinib is designed to target the EGFR T790M resistance mutation, which is the most frequently event responsible for resistance to initial EGFR-TKI treatment in EGFR-mutated NSCLC patients, and patients with this mutation show a better response to osimertinib than to cytotoxic chemotherapy6.